REPOSIT


Protocolnummer:
NL 48639.031.14

Ziekenhuizen:
Erasmus Medisch Centrum Rotterdam
Isala Zwolle
Leids Universitair Medisch Centrum
Maastricht UMC+
Maxima Medisch Centrum Veldhoven
Medisch Spectrum Twente Enschede
NKI / A.v.L ziekenhuis Amsterdam
RadboudUMC Nijmegen
Universitair Medisch Centrum Groningen
Universitair Medisch Centrum Utrecht
VU Medisch Centrum Amsterdam

Titel:
A Phase II, Open-Label, Multicenter Study of Vemurafenib plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV Melanoma; Response Monitoring and Resistance Prediction with Positron Emission Tomography and Tumor Characteristics. REPOSIT.

Behandeling:
Vemurafenib (960mg BID) and Cobimetinib (60mg QD)

Stadium:
Stadium irresectable IIIc/IV

Belangrijkste in/exclusiecriteria:
In: Patient with unresectable stage IIIc or stage IV confirmed BRAF mutation-positive metastatic melanoma, no prior RAF or MEK pathway inhibitor treatment, evaluable disease by CT and PET, ECOG performance status of 0-1. Ex: symptomatic brain metastases, impaired cardiac function, retinal disease.

Contactpersoon:
Prof. J.B.A.G. Haanen / Dr. A.J.M. van den Eertwegh

Alle trials